SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million years of life. Founded by the National Cancer Institute in 1956.
Joined January 2012
- Tweets 15,037
- Following 1,435
- Followers 14,591
- Likes 15,670
2,048 Photos and videos
SWOG Cancer Research Network retweeted
Jun 11
A new #myeloMATCH clinical trial, #CCTG ALC10 has opened in Canada! Exploring a new treatment option for older adults with acute myeloid leukemia #AML who may not be able to tolerate intensive chemotherapy.
buff.ly/ABTpHbj
#Hematology #ClinicalTrials
@BCCancer @SWOG
ALT a picture representing the recently opened #myeloMATCH clinical trial, #CCTG ALC10. Exploring a new treatment option for older adults with acute myeloid leukemia #AML who may not be able to tolerate intensive chemotherapy.
1
1
5
299
SWOG Cancer Research Network retweeted
Thanks @WaqasHaqueMD and @OncData for highlighting our trial S1900J for MET amplification in pts with NSCLC presented at #ASCO26
@LungMAP
@SWOG
@drgandara
@ReckampK
@metcrusaders
After #ASCO26, @ChristianRolfo, @OSUCCC_James, sat down with @WaqasHaqueMD to discuss the evolving role of #MET amplification in stage IV recurrent non-small cell #LungCancer (#NSCLC) and a phase 2 study of subcutaneous #amivantamab.
Watch here! oncdata.com/new-door-in-lung…
1
9
15
1,774
SWOG Cancer Research Network retweeted
Jun 8
Chairs @ALLIANCE_org @SWOG @EAONC myeloma committees.
IMWG meeting.
@szusmani @DoctorAKrishnan @VincentRK
4
16
80
5,886
SWOG Cancer Research Network retweeted
Nivo-AVD now approved in Europe for frontline advanced stage Hodgkin lymphoma based upon @SWOG S1826 trial.
lymphomahub.com/medical-info…
2
7
22
1,499
SWOG Cancer Research Network retweeted
Jun 5
Agree @teamoncology NCORP is the heart & soul of NCI cancer clinical trials. the means by which we "bring the trial to the patient rather than bringing the patient to the trial" at academic center. At Lung MAP, our Lung Master protocol, well over 1/2 accrual is community @SWOG
The @UHCancerCenter is highly active in clinical trials through NCORP and NCTN. Dr. Jeffrey Berenberg, our highly respected senior investigator, serves as our senior principal investigator and has been a key leader in advancing this important work.
NCORP/NCTN studies are equally important to industry-sponsored trials. They help bring high-quality cancer clinical trials to communities and ensure that research addresses the real needs of patients, including those in underserved and geographically isolated areas.
A recent podcast by The Cancer Letter featuring NCORP leaders highlights how cancer clinical trials are becoming increasingly complex. While regulatory oversight is essential for patient safety and research quality, growing administrative requirements can slow progress and take valuable time away from patient care and research execution.
The discussion also emphasizes major challenges facing clinical trials today: workforce shortages, staff turnover, limited funding, low patient participation, and the difficulty of bringing trials to underserved communities. These issues directly affect access, trust, and the ability to deliver high-quality cancer care.
The key message is clear: community involvement is essential. Clinical trials must reach patients where they live. Better outreach, education, training, and thoughtful use of tools such as AI can help reduce barriers and make cancer research more efficient, accessible, and patient-centered.
Cancer research works best when the community is not only included, but truly engaged.
This is a great podcast to listen to.
youtube.com/watch?v=ummAFQno…
3
7
1,541
SWOG Cancer Research Network retweeted
Jun 2
Great to meet with @ChristianRolfo and Tiparna Sen at #ASCO26. Oncologists with NSCLC MET amplified patients should consider the @SWOG @LungMAP subcutaneous amivantamab trial S1900J. Send your patients to the MET Crusaders! @JhanelleGray @drgandara @ReckampK
Very excited to present our trial in progress at #ASCO26
S1900J is enrolling patients in NSCLC with MET amplification as primary driver to be treated with Amivantamab sc
@SWOGonc @LungMAP
@JhanelleGray @drgandara @ReckampK
@OSUCCC_James @OhioStateMedOnc
@metcrusaders
@ASCO
6
10
1,442
SWOG Cancer Research Network retweeted
Next up use of #VitaminD for #taxane induced #CIPN from @SWOG here at #ASCO26 #pallonc abstracts chaired by @MazieTsangMD and @laurenchiec
@MazieTsangMD
@DarcyBurbage
@Chaosdyna
@crisbergerot
@GretchenMcnally
@BbaharK
@asfeen_ummul
@veladconmigo
@FionnualaCrowle
@jillfeldman4
@IshwariaMD
@SrinishantR
@AjuVaniBabu
@rabrazzak
@TamrynGray
@anhbl9
@OncoAlert🚨
#OncoAlertAF
@FadiHaddad_MD
@Abdallah81MD
@Erman_Akkus
@bavilima
@acampsmalea
@DrFMartinelli
@Dr_Ivanoncologo
@orellanauro
@FernandoOnco
@Lucarecco
@HHorinouchi
@ElisaAgostinett
@to_be_elizabeth
@BRicciutiMD
@nataliagandur
@GaiaGriguolo
@JankovicK
@weoncologists
@OncoReporte
@GIMedOnc
@MarioBalsaMD
@DrMirallas
@OscarTahuahua
@DrRishabhOnco
@UOzkerim
@Onco_Cifu88
@DraMartinezLago
@DaisukeKotani
9
18
1,373
SWOG Cancer Research Network retweeted
May 31
@theNCI #SWOG2107 #ASCO26 Phase II of encorafenib cetuximab /- nivo (CMS1) for #BRAFV600MT mCRC. Unfortunately could not validate PFS based on earlier @UTMDAnderson pilot findings. However, it reinforces creating a hypothesis and the need for validation! @VanMorrisMD #cancer #cancerresearch @OncoAlert
5
15
684
SWOG Cancer Research Network retweeted
Jun 1
Exciting presentation #ASCO26 from @RWinayak on microbial dysbiosis as a predictor of CMB588 effectiveness w/IO in metastatic #kidneycancer #mRCC. Thanks for the nod to #BIOFRONT which is now enrolling patients!
1
6
19
1,628
SWOG Cancer Research Network retweeted
Jun 1
Superb presentation by @RWinayak mentee of the amazing @montypal
on microbial dysbiosis as predictor of benefit of microbiome CBM588 when added to ICI in RCC. #ASCO26 @ASCO
Very promising clinical outcomes laying the foundation of the ph 3 BIOFRONT trial led by @PBarataMD @SWOG
Kudos to @montypal for opening the frontier of Microbiome's to enhance ICI efficacy in RCC.
1
18
35
2,051
SWOG Cancer Research Network retweeted
🚨 Final DART trial presentation at #ASCO by @PatelOncology today! Kudos to the whole SWOG-NCI team! @Dr_R_Kurzrock
Comprehensive results from the landmark DART trial (NCI/SWOG S1609) evaluating dual immunotherapy for rare cancers. Rare tumors make up ~22% of all cancer cases but are massively underrepresented—until now.
The details:
🔹 The Treatment: Combined CTLA-4 (ipilimumab) PD-1 (nivolumab) blockade across 53 rare cancer cohorts.
🔹 The Scale: 798 patients enrolled across 1,083 US sites.
🔹 Efficacy: 24 of 53 cohorts (45%) demonstrated clear clinical activity. Meaningful responses seen in rare types like gestational trophoblastic disease, chordoma, and basal cell carcinoma.
🔹 Survival: Median 3-year Overall Survival (OS) reached 23% across these heavily challenging diseases.
🔹 Safety: 14% of patients discontinued treatment due to adverse events (most commonly fever, diarrhea, and rash).
A monumental effort bringing targeted hope to the rare cancer community! 🔬🌟 #OncTwitter #RareCancer #Immunotherapy @SWOG @NUFeinbergMed @LurieCancer @NorthwesternMed @SupportingSWOG @OncoViews @OncoAlert
1
10
28
1,903
SWOG Cancer Research Network retweeted
May 31
DART study 🎯 showed responses in 31 (if I counted correctly) different rare tumor types with ipi nivo. So important for patients with rare cancers. Amazing effort by @Dr_R_Kurzrock @PatelOncology @SWOG supported by @theNCI @NCIDirector #ASCO26
5
25
2,043
SWOG Cancer Research Network retweeted
May 31
A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors. The interim results of the @SWOG S1823 (#CCTG GCC1) study presented at #ASCO26 could identify patients at higher risk of relapse earlier #DrLuciaNappi buff.ly/wLDl01S
2
5
290
SWOG Cancer Research Network retweeted
Pleasure to be inducted into #FASCO this year @ASCO with @SWOG leaders @JhanelleGray #MaryRedman! Volunteering for @ASCO has been the highlight of my career. It isn’t just about accumulating FASCO points but building a community that believes in contributing and giving back.
14
7
72
4,130
.@LungMAP investigators present 4 posters at #ASCO26. 1 is an analysis led by Dr. Diane Tseng of how the severity of immune-related adverse events (irAEs) in patients getting ICIs is associated with clinical outcomes: asco.org/abstracts-presentat… @FNIH_Org @CancerResrch @theNCI @SWOG
4
6
478
SWOG Cancer Research Network retweeted
What can we tell folks w/ taxane-induced peripheral neuropathy after early-stage cancer re: whether it'll recover?
@SWOG 1714, #ASCO26 abs 12117:
- Of 1321 pts, 553 had TIPN at end of tx
- 48.5%, it improved
- 33.8% didn't change
- 17.7% worsened
@MeghnaTrivedi3 @DrDawnHershman
3
9
15
1,707
SWOG researchers give #ASCO26 oral presentations on results of 2 GI trials, a testicular cancer study, work on vit D & neuropathy, big-picture results from S1609 DART rare cancers trial, & an AI prediction model in breast cancer! @SWOG ASCO calendar is at swog.org/media/26051.
8
14
982
SWOG Cancer Research Network retweeted
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] swog.org/clinical-trials/s22… #mmsm #bmtsm
1
3
294
SWOG Cancer Research Network retweeted
May 23
Now accruing: @SWOG S2419 led by @PBarataMD, @montypal, & @DrVaishampayan. The first phase 3 trial testing the addition of CBM-588 to IO-based front-line regimens in mRCC.
@MosheOrnsteinMD @ReginaBarCar @NazliDizman @LauraBukavinaMD @YuWeiChenMD @katy_beckermann @PavlosMsaouel @PGrivasMDPhD @TwoOncDocs @bergsa83 @crisbergerot @KidneyCancer @kidneycan @OncoAlert
We are so proud of @RWinayak, my postdoctoral fellow, who just joined us at @cityofhope. With mentorship & support from @NazliDizman @DanaFarber, he will be gracing the #ASCO26 stage with an update on our work on #CBM588. We have incorporated some novel analysis of #dysbiosis based on a new collaboration with @RobJenqMD, who joined us from @UTMDAnderson. @DrMvandenBrink @hoperugo @DrRaviSalgia @christine_lovly
1
9
31
6,102
SWOG Cancer Research Network retweeted
Ab#5096 @ASCO #ASCO26 by @ggebraelmd👉 bit.ly/3RTHBsc👉Post hoc analysis of @swog 1216 ph3👉Baseline testosterone (≤ vs > median) does not associate w/ outcomes in pts w/ mHSPC #prostatecancer👉baseline T may not assist w/ prognostication👇@OncoAlert @urotoday
2
16
23
2,048